Catechol-O-methyltransferase inhibitor: An Investigational Treatment for Parkinson’s Disease
COMT inhibitors are utilized to prolong the duration of effect of levodopa which is the primary treatment option for Parkinson’s disease patients. Administration of levodopa often results in adequate control of Parkinson’s symptoms, also referred to as “on-time.”; however, there are periods of the day where the effects of levodopa wear off and motor symptoms worsen, referred to as “off-time.” Opicapone is a novel, once-daily, peripherally-acting, highly-selective COMT inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients. Opicapone works through decreasing the conversion rate of levodopa into 3-O-methyldopa, thereby reducing the off-time and extending the on-time period associated with Parkinson’s treatment.
Opicapone Development: BIAL Collaboration
In February 2017, we entered into an exclusive license agreement with BIAL – Portela & CA, S.A. (BIAL) for the development and commercialization of opicapone for the treatment of human diseases and conditions, including Parkinson’s disease, in the United States and Canada. Under the terms of the agreement, we will be responsible for the development and commercialization of opicapone in the United States and Canada.